Formulation: A solid
Formal Name: 4-[6-methoxy-4-[[1,4,6,7-tetrahydro-1-(1-methylethyl)-7-oxospiro[5H-indazole-5,4′-piperidin]-1′-yl]carbonyl]-2-pyridinyl]-benzoic acid
Purity: ≥98%
Formula Markup: C28H30N4O5
Formula Weight: 502,6
Shelf life (days): 1460
CAS Number: 1370448-25-1
Notes: PF-05221304 is an inhibitor of acetyl-CoA carboxylase 1 (ACC1) and ACC2 (IC50s = 12.4 and 8.7 nM, respectively).{67434} It inhibits de novo lipid synthesis (IC50 = 61 nM) and increases fatty acid oxidation in primary human hepatocytes. PF-05221304 reduces the accumulation of triglycerides composed of de novo-derived fatty acids but not dietary essential fatty acids in primary human hepatocytes. In vivo, PF-05221304 (10 and 100 mg/kg) reduces hepatic malonyl-CoA production and de novo lipogenesis in rats. It reduces hepatic fibrosis, alanine transaminase (ALT) and aspartate aminotransferase (AST) levels, and triglyceride accumulation in a rat model of non-alcoholic steatohepatitis (NASH) induced by a choline-deficient and high-fat diet (CDAHFD).
English
Deutsch
